These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23291407)

  • 1. RNA dependent RNA polymerase of HCV: a potential target for the development of antiviral drugs.
    Waheed Y; Bhatti A; Ashraf M
    Infect Genet Evol; 2013 Mar; 14():247-57. PubMed ID: 23291407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-nucleoside inhibitors of the HCV polymerase.
    Sarisky RT
    J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase.
    Eltahla AA; Lackovic K; Marquis C; Eden JS; White PA
    J Biomol Screen; 2013 Oct; 18(9):1027-34. PubMed ID: 23708123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibitors of hepatitis C virus replication.
    Neyts J
    Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleotide prodrugs for the treatment of HCV infection.
    Sofia MJ
    Adv Pharmacol; 2013; 67():39-73. PubMed ID: 23885998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research.
    Haudecoeur R; Peuchmaur M; Ahmed-Belkacem A; Pawlotsky JM; Boumendjel A
    Med Res Rev; 2013 Sep; 33(5):934-84. PubMed ID: 22893620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-hepatitis C virus RdRp activity and replication of novel anilinobenzothiazole derivatives.
    Peng HK; Chen WC; Lin YT; Tseng CK; Yang SY; Tzeng CC; Lee JC; Yang SC
    Antiviral Res; 2013 Oct; 100(1):269-75. PubMed ID: 23994188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.
    Olsen DB; Eldrup AB; Bartholomew L; Bhat B; Bosserman MR; Ceccacci A; Colwell LF; Fay JF; Flores OA; Getty KL; Grobler JA; LaFemina RL; Markel EJ; Migliaccio G; Prhavc M; Stahlhut MW; Tomassini JE; MacCoss M; Hazuda DJ; Carroll SS
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3944-53. PubMed ID: 15388457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the molecular targets for new therapeutical agents in hepatitis c infection.
    Vagu C; Sultana C; Ruţă S
    Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel tricyclic indole derived inhibitors of HCV NS5B RNA dependent RNA polymerase.
    Venkatraman S; Velazquez F; Gavalas S; Wu W; Chen KX; Nair AG; Bennett F; Huang Y; Pinto P; Jiang Y; Selyutin O; Vibulbhan B; Zeng Q; Lesburg C; Duca J; Huang HC; Agrawal S; Jiang CK; Ferrari E; Li C; Kozlowski J; Rosenblum S; Shih NY; Njoroge FG
    Bioorg Med Chem; 2013 Apr; 21(7):2007-17. PubMed ID: 23434368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to direct antiviral agents in patients with hepatitis C virus infection.
    Sarrazin C; Zeuzem S
    Gastroenterology; 2010 Feb; 138(2):447-62. PubMed ID: 20006612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
    Pawlotsky JM; Najera I; Jacobson I
    Antivir Ther; 2012; 17(3):411-23. PubMed ID: 22402762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
    Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
    Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
    Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
    Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.
    Li H; Shi ST
    Future Med Chem; 2010 Jan; 2(1):121-41. PubMed ID: 21426049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.
    Imran M; Manzoor S; Khattak NM; Khalid M; Ahmed QL; Parvaiz F; Tariq M; Ashraf J; Ashraf W; Azam S; Ashraf M
    Arch Virol; 2014 May; 159(5):831-46. PubMed ID: 23979177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.